Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bruker Granted FDA Clearance to Market the MALDI Biotyper CA System

Published: Tuesday, November 26, 2013
Last Updated: Tuesday, November 26, 2013
Bookmark and Share
Bruker able to market MALDI Biotyper CA System in the US for the identification of Gram negative bacterial colonies cultured from human specimens.

The MALDI Biotyper CA System includes the bench-top microflex™ MALDI-TOF (matrix-assisted laser desorption ionization time-of-flight) mass spectrometer, software, IVD labeled reagents, a 48-spot MALDI target and a library of microorganism reference spectra. Bruker has conducted a multi-site clinical trial comparing performance of the MALDI Biotyper CA Systemto 16S ribosomal RNA gene sequencing. The overall accuracy of the MALDI Biotyper CA System was comparable to that of nucleic acid sequencing. FDA clearance of the MALDI Biotyper CA System is the latest achievement in Bruker’s continuous efforts to develop MALDI-TOF mass spectrometry into the most advanced platform for clinical microbiology identification.

In 2009, Bruker launched a MALDI Biotyper system in compliance with the European in vitro diagnostic directive EC/98/79, making the CE-IVD labelled IVD-MALDI Biotyper the first MALDI-TOF based product registered for use in European clinical microbiology laboratories. Since then, Bruker has continued its effort to expand into routine clinical microbiology and other markets throughout the world. Currently the CE-IVD labelled IVD-MALDI Biotyper is available for clinical microbiology routine usage in Europe, as well as in many countries around the world, including Canada, Argentina, Mexico, Colombia and Ecuador in theAmericas and in Japan, Hong Kong, Singapore, Malaysia and Taiwan in Asia/Pacific.

Frank Laukien, President and Chief Executive Officer of Bruker Corporation, commented: “We are very excited about this major milestone in our effort to introduce MALDI-TOF mass spectrometry into clinical diagnostics. For the last seven years Bruker has been working on continuous innovation in the field of MALDI-TOF-based microbial identification, bringing theMALDI Biotyper platform into clinical routine laboratories. The MALDI Biotyper has been a success with more than 1,000 systems sold or leased worldwide, which has positively affected the health of many patients. Bruker has initiated a continuing revolution in clinical microbiology towards the MALDI Biotyper as a next-generation identification technique. With clearance by the US FDA to market the MALDI Biotyper CA System, we expand our market reach into the largest clinical market in the world, with expected significant improvements in outcomes and reductions in the cost of healthcare.”

Dr. Robert Jerris, PhD, D (ABMM), the Director of Clinical Microbiology at the Children´s Healthcare of Atlanta pediatric hospital, added: “MALDI-TOF has had a dramatic impact on patient care at Children’s Healthcare of Atlanta. The ability to identify organisms directly from plates - saving at minimum a day over conventional phenotypic tests for many organisms - has impacted therapy, timely infection control and contributed to decrease in healthcare expenditures. Outcome studies have shown such significant positive results that it is predictable to say that this technology will eventually be a staple in clinical microbiology.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bruker Reports First Quarter 2016 Financial Results
Bruker Corporation reported financial results for its first quarter ended March 31, 2016.
Wednesday, May 11, 2016
PREMIER Biosoft Announces Reseller Agreement with Bruker
Agreement aims to advance lipidomics and metabolomics research.
Monday, November 17, 2014
Bruker Sells GC Business
Bruker completed the divestiture of its GC and GC single-quadrupole (GC-SQ) mass spectrometry products to Techcomp Europe Ltd on October 31st.
Tuesday, November 04, 2014
Using LC-MS to Analyse Sulfonamides in Food Grade Honey
Sulfonamides are one of a number of groups of chemicals whose presence in honey is limited by international regulations.
Tuesday, July 22, 2014
Bruker MALDI Biotyper™ Receives CFDA Clearance
Company receives clearance from the China Food and Drug Administration to market and sell its IVD MALDI Biotyper System as a medical device in China for the identification of microorganisms isolated from human specimens.
Thursday, June 26, 2014
Bruker Reports 7% Revenue Growth in Q4
Bruker Corporation reported financial results for its fourth quarter and full year ended December 31, 2013.
Wednesday, February 19, 2014
Bruker and SISCAPA Assay Technologies Announce Second-Phase Collaboration Agreement
The ongoing collaboration aims to exploit MALDI-TOF instruments as an alternative to nano-LC-MS technology currently used in many SISCAPA assays.
Monday, September 16, 2013
Bruker and ImaBiotech Announces Collaboration
Bruker to distribute ImaBiotech's Quantinetix software for quantitative MALDI imaging.
Friday, June 21, 2013
Bruker and 3M Sign Exclusive Patent License Agreement
The licensed 3M patents are directed to a technique for performing mass spectrometry analysis on proteins in tissue that has been preserved in paraffin.
Tuesday, June 04, 2013
Bruker and SCiLS GmbH Announce an Exclusive Partnership
SCiLS Lab is the software developed by SCiLS GmbH which allows the user-friendly statistical analysis of large MALDI imaging datasets.
Wednesday, May 15, 2013
Biodesix Announces Agreement with Bruker Daltonics
The collaborative agreement sees Bruker Daltonics support Biodesix’ VeriStrat diagnostic test as well as future diagnostic tests based on MALDI-TOF mass spectrometry.
Wednesday, April 24, 2013
Bruker and the Genome British Columbia Proteomics Centre to Collaborate
The collaborative effort covers the development and validation of high-throughput assays for determining hemoglobin variants and diabetes risk.
Thursday, April 18, 2013
Bruker and Erasmus Medical Center Sign an Exclusive Licensing Agreement
Agreement for adding rapid beta-lactamase testing capabilities to the MALDI Biotyper system.
Friday, January 04, 2013
Bruker Announces New UK Centre of Excellence
Company introduces its integrated, state-of-the-art demonstration, applications and customer collaboration facilities.
Wednesday, October 03, 2012
Bruker and JMI Laboratories Announce Collaboration for Mass Spectrometry
The collaboration sees Bruker and JMI Laboratories partner in the field of fungal identification by proteomics fingerprinting.
Wednesday, June 20, 2012
Scientific News
Detecting Fake Parmesan Cheeses
Scientists report on a way to catch adulteration of the regional artisanal products.
The Need for Speed
Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.
Process Analysis in Real Time
With a real-time mass spectrometer developed by Fraunhofer researchers, it has become possible for the first time to analyze up to 30 components simultaneously from the gas phase and a liquid, including in-situ analysis.
Triple-Negative Breast Cancer Target Is Found
Researchers at UC Berkeley discover a target that drives cancer metabolism in triple-negative breast cancer.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
A Mechanistic Tool for Studying Fungal Pathogens
This study presents an overview of lipid extraction, chromatographic separation and mass spectrometry employed in qualitative and quantitative sphingolipidomics in fungi.
Newborn Screening Test Developed For Rare, Deadly Neurological Disorder
Scientists have developed a new dried blood spot screening test for Niemann-Pick type C, with goal to speed diagnosis and treatment.
HIV Particles Used to Trap Intact Mammalian Protein Complexes
Belgian scientists from VIB and UGent developed Virotrap, a viral particle sorting approach for purifying protein complexes under native conditions.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Coding and Computers Help Spot Methane, Explosives
Coded apertures improve and shrink mass spectrometers for field use.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!